• Explore /
  • Poster
  • / A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

Abstract Video & Slides Poster

Authors

null

Makoto Ueno

Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Japan

Makoto Ueno , Chigusa Morizane , Masafumi Ikeda , Kentaro Sudo , Yoshinori Hirashima , Masataka Kuroda , Yuki Fukuyama , Takuji Okusaka , Junji Furuse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

JapicCTI-184230

DOI

10.1200/JCO.2022.40.4_suppl.553

Abstract #

553

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Masato Ozaka

First Author: Andrew Dean

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.

Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX.

First Author: Masahiro Yanagi

First Author: Philip Agop Philip